ImmunoGen, Inc. (NASDAQ: IMGN) today announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE